Zogenix to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4

Rhea-AI Summary

Zogenix (NASDAQ: ZGNX) announced it will report its third-quarter financial results for the period ending September 30, 2021, on November 4, 2021, at 4:30 PM Eastern Time. A conference call will follow, providing updates on the company's ongoing research in rare diseases, including therapies for conditions like Dravet syndrome and Lennox-Gastaut syndrome. Zogenix has received approvals for its first therapy, FINTEPLA, in both the U.S. and Europe, with additional late-stage programs underway and plans for further research into genetic epilepsies.

Positive

• Zogenix has successfully developed FINTEPLA, approved by the U.S. FDA and the European Medicines Agency.
• The company is advancing late-stage development programs targeting rare diseases, including Lennox-Gastaut syndrome and TK2 deficiency.
• Plans to initiate studies of FINTEPLA in CDKL5 Deficiency Disorder (CDD) indicate potential growth avenues.

Negative

• None.

EMERYVILLE, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call and webcast after the market close on Thursday, November 4, 2021, at 4:30 PM Eastern Time.

Conference Call Details
Thursday, November 4, at 4:30 PM Eastern Time / 1:30 PM Pacific Time
Toll Free:	855-327-6838
International:	604-235-2082
Conference ID:	10016695
Webcast:	http://public.viavid.com/index.php?id=146849

About Zogenix 
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CONTACTS:

Zogenix
corpcomms@zogenix.com

Investors
Brian Ritchie 
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com

Media
Trish McCall, Porter Novelli
+1 (805) 390-3279 | trish.mccall@porternovelli.com

FAQ

What date will Zogenix report its Q3 2021 financial results?

Zogenix will report its Q3 2021 financial results on November 4, 2021.

What is FINTEPLA and its significance for Zogenix?

FINTEPLA is Zogenix's first therapy approved for Dravet syndrome, representing a major milestone in the treatment of rare diseases.

When is the Zogenix conference call scheduled?

The Zogenix conference call is scheduled for November 4, 2021, at 4:30 PM Eastern Time.

What other diseases is Zogenix developing therapies for?

Zogenix is also developing therapies for Lennox-Gastaut syndrome and TK2 deficiency, among other rare diseases.